RayzeBio raises $45M to advance radiopharmaceuticals

By AuntMinnie.com staff writers

October 14, 2020 -- RayzeBio has raised $45 million in a round of series A financing to advance the development of its targeted radiopharmaceuticals for cancer therapies.

The funds will be used to advance the company's pipeline of drugs against validated cancer targets and focus on delivering the alpha-emitting radioisotope actinium-225. The investors are venBio Partners, Versant Ventures, and Samsara BioCapital.

Copyright © 2020 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking